Prescribing guide
Takhzyro (lanadelumab-flyo)Dosing by age, the every-4-week option, Start Form enrollment and prior authorization criteria for hereditary angioedemaFor prescribers and their offices treating hereditary angioedema (HAE): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS; Start Form (the prescription) by fax or online, prior authorization, specialty pharmacy dispensing, and injection training before the first self-injection.
Example PA threshold
Cigna example: HAE type I or II with functional C1-INH under 50% and low C4, both documented; allergist, immunologist or HAE specialist; labeled dosing; no concomitant preventive HAE therapy.
Monitoring
No scheduled lab monitoring in the label; watch for hypersensitivity; aPTT may be prolonged by assay interference; reassess attack control before considering q4wk dosing after more than 6 months.
Support line
Takeda Patient Support, 1-866-888-0660, Monday to Friday 8:30 AM to 8:00 PM ET; Start Form fax 1-855-663-7284; co-pay help up to 100% of out-of-pocket costs to an annual maximum for commercial plans; Quick Start up to 2 months free while benefits are verified.
Give your patient their plan
A one-page handout for starting Takhzyro, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/takhzyroBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| No REMS | The label sets no REMS, no boxed warning and no contraindications, and Takhzyro does not appear on the FDA REMS list. | FDA REMS list |
| Start Form | Acts as the prescription and the patient's authorization for support services. It needs full patient contact details, the patient's name on each page, prescriber certifications and signature, 1 starting dosage, the support enrollment box and the patient signature. | Enrollment steps |
| Quick Start Program form | Up to 2 months at no cost for commercially insured patients while benefits are verified. The starting dosage must match Section 4 of the Start Form, and a wet prescriber signature is required. Medicare and Medicaid patients are not eligible. | Enrollment steps |
| Submission by fax | Fax the Start Form and the Quick Start form to 1-855-663-7284. Takeda Patient Support begins the benefits investigation and lets the office know of any next steps; a PA will generally be required. | Enrollment steps |
| Online enrollment and services | Enroll online at TakedaPatientSupport.com/HCP. Services include PA information for office staff, benefits investigation, specialty pharmacy or site of care triage, and product administration training, at home if the office requests it. | HCP patient services |
| Patient contact | A support specialist calls the patient within 2 to 4 days if they consented. Advise the patient to save 1-866-888-0660 to avoid spam blockers. | Enrollment steps |
| Injection training | Train the patient or caregiver in subcutaneous technique and confirm the ability to inject before self-administration. Ages 2 to under 12 are dosed by a healthcare provider or caregiver; self-injection is not recommended. | FDA label |
| Appeals | Takeda provides formulary exception, intent to treat, medical necessity, claim denial and coverage denial letter templates. Takeda Patient Support answers office questions on denials and appeals. | HCP enrollment page |
Prior authorization criteria and what to document
One public policy as the example: Cigna, January 1, 2026. Approval approved a year at a time. Renewal asks for HAE type I or II and a favorable response, such as fewer, milder or shorter attacks. This version took effect January 1, 2026. It still cites the February 2023 label, which predates the August 2026 label that removed the vial and added injection site hives. Neither change touches its criteria. Its 2026 update dropped a genetic-test route to diagnosis. Other plans set their own criteria. It is here as an example, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | HAE type I or II, with functional C1-INH below 50% of normal at baseline | C1-INH functional lab report with reference range [documentation required] | Cigna policy |
| C4 | Serum C4 below normal at baseline | C4 lab report with reference range [documentation required] | Cigna policy |
| Exclusion | HAE with normal C1-INH (type III) does not satisfy the diagnosis requirement | Lab results that show C1-INH deficiency | Cigna policy |
| Prescriber | Prescribed by or in consultation with an allergist/immunologist or a physician who specializes in HAE or related disorders | Specialty on the request, or the consult note | Cigna policy |
| Dosing | 300mg no more often than every 2 weeks from age 12; 150mg no more often than every 2 weeks at 6 to under 12; up to 150mg no more often than every 4 weeks under 6 | Age and regimen on the request; other doses reviewed case by case | Cigna policy |
| Combination | Concomitant long-term prophylaxis with other HAE preventives (Cinryze, Haegarda, Orladeyo) is not medically necessary; on-demand and short-term procedural use is allowed | Medication list on the request | Cigna policy |
| Continuation | Diagnosis of HAE type I or II [documentation required] and, per the prescriber, a favorable response such as fewer, less severe or shorter attacks; approval for 1 year | Attack log against pre-prophylaxis baseline | Cigna policy |
Takhzyro dosing and titration
| When | Label | Source |
|---|---|---|
| Age 12 and older | 300mg subcutaneously every 2 weeks, by the patient or caregiver. 300mg every 4 weeks may be considered if well controlled (e.g., attack free) for more than 6 months. | FDA label |
| Age 6 to under 12 | 150mg every 2 weeks, by a healthcare provider or caregiver. 150mg every 4 weeks may be considered if well controlled for more than 6 months. | FDA label |
| Age 2 to under 6 | 150mg every 4 weeks, by a healthcare provider or caregiver. Not established under age 2. | FDA label |
| Presentations | Single-dose prefilled syringes, 1 per carton, 27-gauge ½-inch staked needle: 150mg/mL (NDC 47783-645-01) and 300mg/2mL (NDC 47783-646-01). The single-dose vial was removed from the label in August 2026. | FDA label |
| Administration | Abdomen, thigh or upper arm; remove from the refrigerator 15 minutes before injecting; avoid vigorous agitation; discard any unused portion. | FDA label |
| Pharmacokinetics | Tmax within 5 days; terminal half-life about 2 weeks; steady state at about 70 days. Accumulation ratio about 2.43 on 300mg q2wks. | FDA label |
| Missed dose | The US label gives no missed-dose instruction; agree on a plan with the patient. | FDA label |
| Storage | 2°C to 8°C (36°F to 46°F) in the original carton; do not freeze or shake. The Instructions for Use say to discard a syringe kept out of the refrigerator. | FDA label |
Monitoring the Takhzyro label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Any time | Hypersensitivity | 1% against 0% on placebo in Trial 1; discontinue and institute appropriate treatment for a severe reaction | FDA label |
| Any time | Injection site reactions | 52% against 34% on placebo, mainly pain, erythema and bruising; no meaningful difference with self-administration; injection site urticaria reported postmarketing | FDA label |
| Trial 1 | Transaminases | ALT or AST above 3x ULN in 3.6% and above 8x ULN in 1.2%, none on placebo; asymptomatic and transient; 1 discontinuation at 4.1x ULN AST; no routine monitoring specified | FDA label |
| Coagulation labs | aPTT | May be prolonged by assay interference; not associated with abnormal bleeding in Trial 1; INR unaffected | FDA label |
| After more than 6 months | Attack control | Every-4-week dosing may be considered if well controlled; 44% on 300mg q2wks were attack free over 26 weeks, against 2% on placebo | FDA label |
| Immunogenicity | Anti-drug antibodies | 12% against 5% on placebo in Trial 1, low titer; 15% in the pediatric study; no apparent effect on PK, PD, safety or response | FDA label |
| Renewal | Attack frequency, severity or duration | Cigna approves 1 year at a time; continuation needs a favorable response according to the prescriber | Cigna policy |
Takhzyro drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Other drugs | No dedicated drug interaction studies have been conducted. | FDA label |
| Rescue medications | Plasma-derived and recombinant C1-INH, icatibant and ecallantide used for breakthrough attacks had no effect on lanadelumab-flyo clearance or volume of distribution. | FDA label |
| Common concomitant classes | Analgesic, antibacterial, antihistamine, anti-inflammatory and anti-rheumatic medications had no effect on clearance or volume of distribution. | FDA label |
| aPTT assay | Plasma kallikrein inhibition can increase aPTT; one aPTT of 1.5x ULN or more was confounded by heparin. | FDA label |
| Renal impairment | Mild and moderate renal impairment had no effect on clearance or volume of distribution in population PK. | FDA label |
| Pregnancy and lactation | No human pregnancy data; IgG crosses the placenta mainly in the third trimester; no fetal harm in monkeys at 33 times the MRHD exposure. Detected in monkey milk at about 0.2% of maternal plasma. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedCigna asks for a functional C1-INH level under 50% of normal and a low C4 level, each with lab documentation. It also wants an allergist, immunologist or HAE specialist. The policy marks both lab results as required documents, so the office sends both reports.
- An appeal after a denialTakeda's prescriber site offers appeal templates, including a statement of medical necessity and a formulary exception letter. Takeda Patient Support can answer the office's questions about denials and appeals. The office files the appeal.
- HAE with normal C1-INHCigna's policy says HAE with normal C1-INH, also called type III, does not meet its diagnosis requirement. The Takhzyro label describes its main trial in type I and type II HAE. The allergist can explain the diagnosis to the plan.
- Another preventive medicine at the same timeCigna lists Takhzyro used with other preventive HAE medicines, such as Cinryze, Haegarda or Orladeyo, as not medically necessary. Medicines that treat an attack, or prevent one around a procedure, are allowed.
- A dose the plan will not coverCigna approves 300mg no more often than every 2 weeks from age 12, and 150mg on the label's schedules for children. Other doses go to case-by-case review by a Cigna clinician.
- A copay you cannot payWith commercial insurance, the Takeda co-pay program can cover up to 100% of out-of-pocket co-pays, up to a yearly maximum. Medicare, Medicaid, TRICARE, VA and other government plans are excluded. Takeda says it may connect people who cannot afford treatment to other programs.
- The plan uses a co-pay maximizerTakeda says it may lower or end co-pay help for people in a plan with a co-pay maximizer program. Its terms ask you to tell the program at 1-866-888-0660 if you learn your plan uses one.
Takeda Patient Support
- A support specialist who reviews your coverage and explains financial options
- The Takeda Patient Support Co-Pay Assistance Program for commercial insurance, including Marketplace plans, covering up to 100% of out-of-pocket co-pays up to a yearly maximum
- No co-pay help for Medicare, Medicare Advantage, Medicaid, TRICARE, VA or other federal or state plans
- Work with your specialty pharmacy to get Takhzyro to you
- In-home injection training from a specially trained nurse
- The Quick Start Program, up to 2 months of Takhzyro at no cost for commercially insured patients while benefits are verified Enrollment steps
- Help over the phone in other languages through a translation service
Questions prescribers' offices ask about Takhzyro
What is the Takhzyro dose?
300mg subcutaneously every 2 weeks from age 12, per the August 2026 label (section 2.1); 300mg every 4 weeks may be considered if well controlled, such as attack free, for more than 6 months. Ages 6 to under 12 start at 150mg every 2 weeks with the same q4wk option, and ages 2 to under 6 take 150mg every 4 weeks (section 2.2).
Does Takhzyro have a REMS or required lab monitoring?
No. The August 2026 label has no REMS, no boxed warning, no contraindications and no scheduled lab monitoring, and Takhzyro is not on the FDA REMS list. The one warning is hypersensitivity; discontinue and treat if a severe reaction occurs (section 5.1).
Does Takhzyro affect coagulation tests?
Yes. Per the August 2026 label (section 7.1), Takhzyro can prolong aPTT because the assay activates plasma kallikrein; aPTT above 1x ULN occurred in 11 patients on 300mg q2wks against 5 on placebo in Trial 1. None was associated with abnormal bleeding, and INR did not differ.
How do I enroll a patient in Takeda Patient Support?
Fax the Takhzyro Start Form, which serves as the prescription, to 1-855-663-7284, or enroll online at TakedaPatientSupport.com/HCP. Commercially insured patients can also get up to 2 months free through the Quick Start Program while benefits are verified; the prescriber must sign, and stamps are not accepted.
What do insurers ask for to approve Takhzyro?
The Cigna policy shown here, effective January 1, 2026, asks for HAE type I or II with functional C1-INH under 50% of normal and a low C4, both documented, and an allergist, immunologist or HAE specialist. Approval is for 1 year; HAE with normal C1-INH does not qualify, and concomitant preventive HAE therapy is not covered. It cites the February 2023 label.
Free email alert
Get an email when the Takhzyro label changes
One email the day the FDA revises the Takhzyro prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Takhzyro only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - TAKHZYRO- lanadelumab-flyo injection, solution (prescribing information revised 8/2026, Patient Information revised 8/2026, Instructions for Use approved 8/2026), Takeda Pharmaceuticals America, Inc., via DailyMed, 2026-09-18.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-10.
- Personalized Product Support | TAKHZYRO® (lanadelumab-flyo), Takeda, 2026-11-10.
- Follow these 4 simple steps (TAKHZYRO patient enrollment by fax), Takeda, 2026-11-10.
- Patient Enrollment | TAKHZYRO® (lanadelumab-flyo), Takeda, 2026-11-10.
- Patient Support | TAKHZYRO® (lanadelumab-flyo), Takeda, 2026-11-10.
- Hereditary Angioedema, Takhzyro, Drug Coverage Policy IP0334, Cigna, 2026-01-01.
- BLA 761090/S-020 supplement approval letter, injection site urticaria and removal of the single-dose vial, FDA, 2026-08-20.
- BLA 761090/S-010 supplement approval letter, pediatric patients 2 to less than 12 years, FDA, 2023-02-03.
- TAKHZYRO prescribing information, revised 02/2022 (BLA 761090/S-003), FDA, 2022-02-08.
- BLA 761090/S-001 supplement approval letter, Highlights formatting change, FDA, 2018-11-16.
- BLA 761090 approval letter, TAKHZYRO (lanadelumab-flyo), FDA, 2018-08-23.
A reference drawn from the September 18, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 10, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.